Business Description
Iovance Biotherapeutics Inc
NAICS : 325411
SIC : 2834
ISIN : US4622601007
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 4.22 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | -0.2 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 4.72 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 0.2 | |||||
3-Year EPS without NRI Growth Rate | -0.2 | |||||
3-Year FCF Growth Rate | 3.6 | |||||
3-Year Book Growth Rate | -20.1 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 21.63 | |||||
9-Day RSI | 31.21 | |||||
14-Day RSI | 36.18 | |||||
6-1 Month Momentum % | 155.11 | |||||
12-1 Month Momentum % | 55.07 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.63 | |||||
Quick Ratio | 4.42 | |||||
Cash Ratio | 4.28 | |||||
Days Inventory | 237.57 | |||||
Days Sales Outstanding | 26.71 | |||||
Days Payable | 570.62 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.4 | |||||
Shareholder Yield % | -13.35 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | -846.22 | |||||
Operating Margin % | -24549.63 | |||||
Net Margin % | -23615.7 | |||||
FCF Margin % | -21274.19 | |||||
ROE % | -70.61 | |||||
ROA % | -55.04 | |||||
ROIC % | -107.6 | |||||
ROC (Joel Greenblatt) % | -259.74 | |||||
ROCE % | -64.49 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1335 | |||||
PB Ratio | 4.39 | |||||
Price-to-Tangible-Book | 7.67 | |||||
EV-to-EBIT | -5.62 | |||||
EV-to-Forward-EBIT | -5.22 | |||||
EV-to-EBITDA | -6.11 | |||||
EV-to-Forward-EBITDA | -5.22 | |||||
EV-to-Revenue | 1380.57 | |||||
EV-to-Forward-Revenue | 79.72 | |||||
EV-to-FCF | -6.71 | |||||
Price-to-Net-Current-Asset-Value | 15.1 | |||||
Price-to-Net-Cash | 17.84 | |||||
Earnings Yield (Greenblatt) % | -17.79 | |||||
FCF Yield % | -13.97 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Iovance Biotherapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 1.759 | ||
EPS (TTM) (€) | -1.664 | ||
Beta | 1.06 | ||
Volatility % | 151.42 | ||
14-Day RSI | 36.18 | ||
14-Day ATR (€) | 0.521892 | ||
20-Day SMA (€) | 11.1761 | ||
12-1 Month Momentum % | 55.07 | ||
52-Week Range (€) | 3.107 - 16.85 | ||
Shares Outstanding (Mil) | 279.83 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Iovance Biotherapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Iovance Biotherapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Iovance Biotherapeutics Inc Frequently Asked Questions
What is Iovance Biotherapeutics Inc(FRA:2LB)'s stock price today?
When is next earnings date of Iovance Biotherapeutics Inc(FRA:2LB)?
Does Iovance Biotherapeutics Inc(FRA:2LB) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |